LakePharma Announces Dedicated Vector Center to Support Gene and Cell TherapyAdded On: 2019-02-26
LakePharma Announces its GMP Biorepository Facility near Boston is Now Operational, Plans Additional HiringAdded On: 2019-01-15
LakePharma announces its cGMP microBiomanufacturing Center is now operationalAdded On: 2018-12-18
Added On: 2016-04-22
LakePharma's CEO Hua Tu will present at PEGS Boston on Tuesday April 26, 2016.
Dr. Tu will share data for the design, engineering, bioanalytical characterization and manufacturability assessment of Fc fusions and bispecific antibodies.
Company scientists will also present a poster detailing a tandem mass spectrometry approach to proteomic sequencing that enables the accurate determination of an antibody’s primary sequence when the source hybridoma is unavailable. In addition to revealing the full sequence of an important antibody, their approach enabled the engineering of the antibody to improve its production by CHO cells, as well as its performance as a purification reagent.
Details on Poster Sessions